A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly’s popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.S. Food and Drug Administration’s decision last year that there was no longer a shortage of the medicines’ active ingredient, tirzepatide.
About the Author
